|

Degarelix Clinical Trials

11 actively recruiting trials across 11 locations

Also known as: ASP 3550, ASP-3550, ASP3550, FE 200486, FE-200486, FE200486, Firmagon, Firmagon Kit, GnRH antagonist, Ovarian suppression

Birmingham, Alabama1 trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

University of Alabama at Birmingham Cancer Center

Phase 3

Anchorage, Alaska1 trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona1 trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona1 trial

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic in Arizona

Phase 2

Duarte, California1 trial

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

Phase 2

Aurora, Colorado1 trial

Cardiometabolic Consequences of the Loss of Ovarian Function

University of Colorado Anschutz Medical Campus

Phase 4

Washington D.C., District of Columbia1 trial

ETHAN - ET for Male BC

Georgetown University Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Providence, Rhode Island1 trial

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Lifespan Cancer Institute

Phase 1

Houston, Texas1 trial

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M D Anderson Cancer Center

Phase 2

Madison, Wisconsin1 trial

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

University of Wisconsin Carbone Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.